Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

Rep. Cory Mills (R-FL) sent a letter Tuesday to the chairman of Sichuan Kelun-Biotech Biopharmaceutical, Mr. Liu Gexin, "demanding answers to serious allegations regarding their ties to the Chinese C ...

Mr. Kennedy appears to have most Republicans behind him as he seeks the job of health secretary, though he couldn’t escape ...

A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

The Food and Drug Administration’s approval of low-risk tobacco pouches is welcome, but why did it delay for more than four ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Express Scripts aims to ensure that patients directly benefit from its negotiations with drug manufacturers. The new approach will protect patients from paying inflated list prices for medications, ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. Could this be a great buying ...